The question of selecting the "best" amongst different choices is a common problem in statistics. In drug development, our motivating setting, the question becomes, for example: which treatment gives the best response rate. Motivated by a recent development in the theory of context-dependent information measures, we propose an experimental design based on a simple and intuitive criterion to govern arm selection in an experiment with multinomial outcomes. The criterion leads to reliable selection of the correct arm without any parametric or monotonicity assumptions. The asymptotic properties of the design are studied for different allocation rules and the small sample size behaviour is evaluated in simulations in the context of Phase I and Phase II clinical trials. We compare the proposed design to currently used alternatives and discuss its practical implementation.
Introduction
Over the past decades a variety of different methods for clinical trials aiming to select the "optimal" arm (e.g. dose, treatment, combination of treatments,...) have been proposed in the literature (O'Quigley and others, 1990; Wages and others, 2011; Magirr and others, 2012; Villar and others, 2015; Lee and others, 2016) . Given m arms, the aims of Phase I and Phase II clinical trials are often to identify the target arm (TA) corresponding to the toxicity probability closest to the target 0 < γ t < 1 and/or the efficacy probability closest to the target 0 < γ e < 1. Despite the similar problem formulation for Phase I (evaluating toxicity) and Phase II (evaluating efficacy) trials, quite different approaches are generally utilized.
In Phase I dose-escalation trials, model-based designs assuming a monotonic dosetoxicity relationship are shown to have good operating characteristics in the setting of a single cytotoxic drug (Iasonos and others, 2016) . The ability to find the TA using these methods is, however, rather limited if the assumption of monotonicity is not satisfied (Shen and O'Quigley, 1996) . While this is not common for cytotoxic drugs, the uncertainty about toxicity and efficacy orderings holds for drugs combinations, dose-schedules and molecularly targeted drugs (Wages and others, 2011; Lagarde and others, 2015) .
To overcome the issue of an unknown ordering in the context of Phase I trials, some specialised approaches for combination and dose-schedule trials have been proposed (e.g. Thall and others, 2003; Wages and others, 2011; Guo and others, 2016) . The common features of the majority of novel Phase I methods relaxing the monotonicity assumption is either relying on a parametric model or on explicit order of toxicity/efficacy. While such methods allow to borrow information across treatment arms, they might fail to find the TA if the model or ordering is misspecified. There is also growing interest in advanced trials with a large number of potential orderings where specifying all of them (or a corresponding parametric model) is not feasible (see e.g. Mozgunov and Jaki, 2018 , for an example). In addition, more complex outcomes than a simple binary endpoint are becoming more frequent in dose-finding trials (see e.g. Yuan and others, 2007; others, 2010, 2017) as they can carry more information about the drug's mechanism of action. Despite this, methods for studies with complex outcomes that do not require monotonicity or a complex model are sparse to date.
Thinking more broadly about selecting one or more arms during a trial (the main objective of many Phase II studies), different methods that consider arms being independent have been proposed (see e.g. Stallard and Todd, 2003; Koenig and others, 2008; Whitehead and Jaki, 2009; Magirr and others, 2012) . Williamson and others (2016) have recently advocated designs maximising the expected number of responses in small populations trials. As a result, adaptive randomisation methods and optimal multi-arm Bandit (MAB) approaches are starting to be considered more commonly in Phase II clinical trials. Although, MAB designs outperform other well-established methods of randomization (e.g. fixed randomization) in terms of expected number of successes, they can suffer low statistical power for testing comparative hypotheses. This problem corresponds to the 'exploration vs exploitation' trade-off (Azriel and others, 2011) and some rule-based modifications have been proposed archive a better balance of the two objectives (see e.g. Villar and others, 2015; Williamson and others, 2016) . However, the majority of MAB approaches consider univariate binary response only and hone in on the arm with the largest effect by default and cannot be applied to clinical trials which aim to select the TA corresponding to the target probability γ e where γ is often between (0.7, 1). On the other hand, model-based alternatives suffer from the problem of model misspecification. Although, some of these challenges can be overcome by methods such as MCPmod (Bretz and others, 2005) , we believe that flexible alternatives that can be potentially used in the described settings are required.
Overall, the research problems described above can be considered as the general issue of correct identification of the TA whose response probability is closest to the percentile 0 < γ < 1 or equivalently in the multidimensional case, whose characteristics are closest to the vector γ ∈ S d where S d is a d-dimensional unit simplex defined in (2.1). We propose a general experimental design for studies with multinomial outcomes to solve this generic problem. Based on developments in the information theory of context-dependent measures of information (Belis and Guiasu, 1968; Kelbert and Mozgunov, 2015; Kelbert and others, 2016) , we derive a criterion which governs arm selection in the experiment. The criterion is based on the maximisation of the information gain when considering an experiment with a particular interest in arms whose response probabilities are in the neighbourhood of γ. Recently other designs using the information gain principle have been proposed (see e.g. Barrett, 2016; Kim and Gillen, 2016) . In contrast to these methods, the proposed approach allows incorporation of the context of the outcomes (e.g. avoid high toxicity or low efficacy) in the information measures themselves. This is achieved by assigning a greater "weight" to the information obtained about arms with characteristics close to the desired level. Another difference to the majority of information-theoretic approaches is that the design is based on the so-called "patients' gain" which allocates each new patient to the treatment that is considered best while taking into account the uncertainty about the estimates for each arm. This leads to fulfilling of statistical goals of the experiment under the ethical constraints.
The proposed criterion is not restricted to a particular model and can be used, for examples, to govern selection within traditional parametric designs. However, motivated by relaxing parametric and monotonicity assumptions, we demonstrate that good operating characteristics of the design can be achieved without employing these assumptions. For the special case of a complex combination-schedule clinical trial the proposed design has already been shown to be superior compared to currently employed methods and to be practically applicable to an ongoing clinical trial (Mozgunov and Jaki, 2018) . In this work, we generalise the approach for an arbitrary number of outcomes and general class of "weight" functions, study the asymptotic behaviour of the design and compare the performance to the currently used method in contexts of Phase I and Phase II trials.
The remainder of the paper is organized as follows: derivations of the criterion and assignment rules are given in Section 2. The asymptotic behaviour is studied in Section 3. Section 4 presents illustrative examples of the design together with a comparisons to alternative methods. We conclude with a discussion in Section 5.
Methods
The novel design is based on the maximisation of the information gain in the experiment with an interval of the specific interest (neighbourhood of γ). Below, we derive an explicit formula for the information gain in the context of a trial with multinomial outcomes.
Information-theoretic concepts
Consider a discrete random variable taking one of d values and a corresponding random probability vector
Assume that Z has a prior Dirichlet distribution Dir(v + J) where
After n realizations of a discrete random variable in which x (i) outcomes of i are observed, i = 1, . . . , d, the random vector Z n has a Dirichlet posterior distribution with density function
is the Beta-function and Γ(x) is the Gamma-function.
Let α = α (1) , . . . , α (d) T ∈ S d be the vector in the neighbourhood of which f n concentrates as n → ∞. A classic question of interest in this setting is to estimate the probability vector, α. The information required to answer the estimation question can be measured by the Shannon differential entropy of f n (Cover and Thomas, 2012) 
f n (p|x)logf n (p|x)dp (2.3) with convention 0 log 0 = 0. The classic formulation of the estimation question, however, does not take into account the fact that an investigator would like to find the target arm (TA) having pre-specified characteristics
It does not also reflect that one would like to have more precise estimation about the vector α for those arms only which have characteristics close to γ. This is a consequence of the fact that the classic information measures do not depend on the nature of the outcomes p, but on the probability of the corresponding event f (p) and therefore are called context-free. While it gives the notion of information great flexibility which explains its successful application in various fields, the context-free nature might be considered as a drawback in many application areas as it would be demonstrated below.
To take into account the context of the experiment and the nature of the outcomes p, one can consider an estimation experiment with "sensitive" area (i.e. the neighbourhood of γ). The information required in such an experiment can be measured by the weighted Shannon differential entropy (Belis and Guiasu, 1968; Clim, 2008; Kelbert and Mozgunov, 2015; Kelbert and others, 2016) of f n with a positive weight function φ n (p)
The crucial difference between the information measures given in Equation (2.3) and Equation (2.4) is the weight function, φ n (p), which emphasizes the interest in the neighbourhood of γ rather than on the whole S d . It reflects that the information about the probability vector which lies in the neighbourhood of γ is more valuable in the experiment.
Due to the limited sample size in an actual studies, an investigator is typically interested in answering the question: Which arm has an associated probability vector closest to γ while ensuring accurate estimation of the probability vector for the TA only. For this question, the information gain from considering the experiment with sensitive area equals to
Following the information gain approach, the first term in the equation above is the information in a classic experiment using context-free measure, while the second (novel) term is the information when the context of events is taken into account. Alternatively, ∆ n can be considered as an average amount of the additional statistical information required when considering the context-dependent estimation problem instead of the traditional one.
The information gain in Equation (2.5) requires specification of a weight function which defines the "value" of the information in different areas of the simplex S d . To track the influence of the weight function explicitly we consider a weight function in the Dirichlet form:
where κ ∈ (0, 1) is a parameter and C(x, γ, n) is a constant which is chosen to satisfy the normalization condition S d φ n (p)f n (p|x)dp = 1. The parameter κ is restricted to the unit interval to ensure asymptotically unbiased estimates of the vector α: lim n→∞ S d pφ n (p)f n (p)dp = α. This emphasises the interest in the identification of the TA for the small and moderate sample sizes typical for many applications. The asymptotic behaviour of the information gain, ∆ n , for the family of weight functions (2.6) is studied in Theorem 1. Theorem 1. Let h(f n ) and h φn (f n ) be the standard and weighted differential entropies of (2.2) with weight function (2.6). Let lim n→∞
Proof. The proof is given in the Appendix.
The information gain, ∆ n , tends to 0 for κ < 1/2 which implies that assigning a value of information with rate less than 1/2 is insufficient to emphasize the importance of the context of the study. However, the limit is non-zero for κ ≥ 1/2. Following the conventional information gain approach, one would like to make a decision which maximises the statistical information in the experiment. The information gain ∆ n is always non-positive and for any fixed n its asymptotics achieves the maximum value 0 at the point
(all constants are cancelled out). Indeed, Theorem 1 implies that when maximising the information gain ∆ n , one tends to collect more information about the arm which has characteristics α close to the target γ. To keep the trackable solution which can be easily interpreted in applications, we construct the arm selection criterion using the leading term of the asymptotic expression for ∆ n in Theorem 1:
Note that maximising the leading term of the information gain asymptotics is equivalent to minimising δ (κ) (α, γ). Equation (2.7) can be considered as the measure of the divergence between α and γ and the criterion which governs the selection such that the information gain is maximised. The criterion (2.7) is intuitive as it reflects explicitly the fact that an investigator tends to collect more information about the arm with probability vector close to γ, and also shares some desirable properties. Clearly, δ (κ) (·) ≥ 0 and δ (κ) (·) = 0 iff α = γ for all κ and n. The boundary values α (i) = 0, i = 1, . . . , d correspond to infinite values of δ (κ) (α, γ) which is advocated by Aitchison (1992) as one of the important properties for functions defined on simplex S d . We construct the design based on the selection criterion (2.7) below.
Selection criterion
Consider a discrete set of m arms, A 1 , . . . , A m , associated with probability vectors α 1 , . . . , α m and n 1 , . . . , n m observations. Arm A j is optimal if it satisfies
is introduced where Z n i has the Dirichlet distribution given in (2.2). Let us fix an arm Z n i ≡ Z n and denoteδ
It is a known that a Dirichlet random variable (after appropriate normalization) weakly converges to a multivariate normal distribution. In fact, a stronger result can be shown using the Kullback-
dx where g and f are probability density functions.
Theorem 2. Let Z n = Σ −1/2 (Z n − α) be a random variable with pdf f n where pdf of Z n is given in (2.2) with lim n→∞
Then the Kullback-Leibler divergence of ϕ fromf n tends to 0 as n → ∞ which implies that Z n weakly converges to Z.
Proof. The proof in given in the Appendix.
Using Theorem 2 the following result can be obtained for the proposed criterion.
Theorem 3. Under the assumptions of Theorem 2, letδ
n weakly convergences toZ.
A single summary statistics for δ (κ) (Z n , γ) is needed to select the most promising arm in the sequential experiment. While a Bayesian estimator can be used, we will focus on the intuitively clear and simple 'plug-in' estimator,
, the mode of the posterior Dirichlet distribution. The estimator for the arm A j takes the form
Note that by Theorem 3 for any ε > 0 lim
n j + ε] = 1. The statistics (2.8) is used to govern the selection among arms during the experiment. Note that the estimator above requires a vector of prior parameters v j , j = 1, . . . , m to start the experiment. This choice implies an initial ordering in which an investigator would like to test the arms before the data is available.
Specific Assignment rules
The criterion (2.7) summarizes the arm's characteristics and can be applied to different types of sequential experiments. We consider two assignment rules: Rule I which randomizes between arms and Rule II which selects the "best" arm. These rules follow the setting of the motivating clinical trials: Rule II is widely used in Phase I trials where the randomization to all doses is not ethical or in the typical MAB setting where the primary goal is to maximize the number of successes. Note that randomization (when is ethical) allows to decrease the probability of identifying a suboptimal arm (Thall and Wathen, 2007) .
Rule I: Randomization
Under Rule I, the arm used next in the experiment is randomised with probabilitiesw j ≡
When no observations have yet been collected, the procedure randomizes according to the criterion based on the prior distribution alone,δ (κ) β j , j = 1, . . . , m. Then, given n j observations, x j outcomes for arm A j , j = 1, . . . , m and using the 'plug-in' estimator (2.8), arm A j is selected with probabilityŵ j = 1 ifδ (κ) n j = 0 and with probabilitŷ
The method proceeds until N observations are attained. The arm A j satisfyinĝ
is adopted for the final recommendation, where N i is a total number of observation on an arm A i , i = 1, 2, . . . , m. The value κ = 0.5 in (2.10) is used so that the final recommendation is not penalized by the sample size.
Rule II: Select the best
Let N be a total sample size and begin with the experiment with the arm that minimizeŝ δ (κ) β j , j = 1, . . . , m. Given n j observations, x j outcomes for the arm A j , j = 1, . . . , m and using the 'plug-in' estimator, an arm A j is selected if it satisfiesδ
n i . The method proceeds until the total number of N is attained. Again, we adopt A j as in (2.10) for the final recommendation.
Criterion in the context of clinical trials
Further in the examples (Section 4) we apply the novel selection criterion to Phase I and Phase II clinical trials. In this case the arms are the different treatments (doses, combinations, schedules,...) and the goal is to find the treatment corresponding to specific toxicity (efficacy) characteristics. As the proposed information gain and corresponding selection criterion tends to assign the next patients to the best estimated TA during the trial, the criterion based on ∆ n is a patient's gain (also known as 'best intention' ) criterion as classified by Whitehead and Williamson (1998) . The balance in the 'exploration vs exploitation' trade-off is tuned by the term n 2κ−1 j reflecting the penalty on the number of observations on the same arm (i.e. many observations on one arm would favour selection of other arms). This implies that the design will keep selecting a specific arm only, if the corresponding estimate, α is close γ. As the trial progresses the design requires an increasing level of confidence that the selected arm is the TA. Clearly, κ = 1/2 corresponds to no penalty and is of particular interest in trials with small sample sizes while larger values of κ > 1/2 correspond to a greater interest in the statistical power of the experiment. Importantly, the first term in Equation (2.7) guarantees that the vast majority of patients will be assigned to the TA even for κ > 1/2.
As many Phase I and Phase II clinical trials consider a binary endpoint d = 2 (toxicity:yes/no or response:yes/no), we focus on this case in the examples. Then, (2.2) reduces to the Beta-distribution and the proposed criterion takes the form
which is a normalized distance betweenp
n j and γ. Note that this is not equivalent to the Euclidean distance (p
2 which is a commonly used criterion for selection (see e.g. Shen and O'Quigley, 1996) . As the criterion tends to assign patients to the TA, it still has the Euclidean distance term in the nominator. However, it also takes into account the uncertainty in the denominator which is a variance of the probability of a binary event. The denominator can be also considered as a penalty term which "drives away" the allocation from the bounds (p
n j = 1) as the boundary values correspond to the infinite value of the criterion. Note that, as the maximum variance of the binary probability is achieved atp (i) n j = 0.5, so the criterion favours greater values ofp (i) n j which can be unethical if the objective of a study is to control the risk of toxicity. We will study whether the construction of the criterion creates any practical limitation in the context of Phase I clinical trial in Section 4.2.
Asymptotic behaviour
Considering the asymptotic behaviour of a procedure ensures that the experimental design becomes more accurate as a sample size grows (Azriel and others, 2011) . Recall that the goal of the sequential experiment is to find an arm j which corresponds to the minimum value δ j ≡ δ(α j , γ) among all arms using random variablesδ
Denote the arm to be selected by ν = arg min i=1,...,mδ (κ)
i . Below, we consider the risk-adjusted average approach (Polley and Cheung, 2008) and the probability of correct selection (PCS) (Cheung, 2013) 
where P π j is the probability computed under the vector π j = [α 1,j , . . . , α m,j ]
T , 1 ≤ j ≤ m, which assumes that α j,j corresponds to the TA. The design is consistent if lim N →∞ A N = ∞. The main result of this section is formulated in the following Theorem. Proof. The proof is given in the Appendix.
Examples
In this section the performance of the proposed experimental design is studied in the context of Phase I and Phase II clinical trials under different assignment rules. We will refer to our proposal as the Weighted Entropy (WE) design (WE I under Rule I and WE II under Rule II) and compare its performance to several well-established alternative approaches. All computations have been conducted using R (R Core Team, 2015).
Phase II clinical trial

Setting
Consider a Phase II clinical trial whose primary endpoint is a binary measure of efficacy (e.g. response to treatment). The goals of the study are (i) to find the most effective treatment and (ii) to treat as many patients as possible on the optimal treatment. Clearly, Rule I is preferable for the first goal and Rule II for the second one. We consider two hypothetical trials, each with m = 4 treatments, investigated by Villar and others (2015) for Multi-Arm Bandit models (MAB). We compare the performance of the proposed approach to the MAB approach based on the Gittins index (Gittins and Jones, 1979) , which is the optimal design in terms of maximising expected number of successes (ENS), and to fixed and equal randomization (FR) which is best in terms of the statistical power.
Trial 1 investigates N 1 = 423 and the true efficacy probabilities are (0.3, 0.3, 0.3, 0.5) while Trial 2 considers N 2 = 80 and the scenario (0.3, 0.4, 0.5, 0.6). Following the original application we consider the hypothesis H 0 : p 0 ≥ p i for i = 1, 2, 3 with the family-wise error rate calculated at p 0 = . . . = p 3 = 0.3, where p 0 corresponds to the control treatment efficacy probability. The Dunnett test (Dunnett, 1984) is used for the hypothesis testing in the FR setting. The hypothesis testing for MAB and WE design is performed using an adjusted Fisher's exact test (Agresti, 1992) . The adjustment chooses the cutoff values to achieve the same type-I error as the FR. The Bonferroni correction is used for MAB and WE designs to correct for the multiple testing and the family-wise error rate is set to be less or equal to 5%. Characteristics of interest are (i) the type-I error rate (α), (ii) statistical power (1 − η), (iii) the expected number of successes (ENS) and (iv) the average proportion of patients on the optimal treatment (p * ). The WE design requires specification of the target value which can be specified in many clinical trial by clinicians. This can be defined as the maximum efficacy that they expect to see for the particular diseases. Below we consider the most challenging setting in which no target value is specified and the goal is to simply maximise the number of successes (as in MAB). To achieve this we set the target probability to a value close to 1. The target γ = 0.999 is used which corresponds to the aim "to find the arm with the highest efficacy probability". The vector of the prior mode probabilities p (0) = [0. 99, 0.99, 0.99, 0.99] T is chosen to reflect no prior knowledge about which arm has the highest success probability and that each treatment is considered as highly efficacious until data suggests otherwise. This choice of prior reflects the equipoise principle (Djulbegovic and others, 2000) . We choose β 0 = 5 to ensure enough observations on the control arm and β 1 = β 2 = β 3 = 2 to reflect no prior knowledge for competing arms. We fix κ = 0.5 for WE I and use different values of κ for WE II .
Results
The trade-off between the expected number of successes (ENS) and the statistical power for different values of the penalty parameter κ under Rule II is illustrated in Figure 1 . In both trials, greater values of κ correspond to greater power and lower ENS as the increase in penalty tends to more diverse allocations. The exception is κ ∈ (0.5, 0.55) in Trial 1 where the inconsistency for κ = 0.5 leads to locking-in on the suboptimal treatment. We choose two values of κ for the subsequent comparison. These choices correspond to (i) high ENS, but unacceptable power (dashed line) and (ii) slightly reduced ENS, but higher power (dotted line).
The operating characteristics of considered designs in Trial 1 are given in Table 1 . Under the null hypothesis, the performance of all methods is similar and the type-I error is controlled. Under the alternative hypotheses, the WE II design with κ = 0.55 performs comparably to the MAB in terms of the ENS, but yields almost 10% points increase in power. Nevertheless, it has unacceptable low statistical power which can be increased by using higher values of the penalty parameter (κ = 0.65). It leads to an increase in the power from 0.53 to 0.86 at the cost of the slight (≈ 4%) decrease in the ENS. In fact WE II then has comparable power to the FR, while treating almost 40 more patients on the superior treatment. Another way to increase the statistical power is to use WE I for which both the associated power and the ENS is higher than for the FR.
The operating characteristics of the designs for Trial 2 with fewer patients and a linear increasing trend is given in the perform similarly and type-I errors are controlled at the 5% level. Under the alternative hypothesis, the MAB and WE II with κ = 0.55, again, yield the highest (and similar) ENS among all alternatives, but also low statistical power. The WE I or increased κ for WE II result in a considerable power increase. Both designs have a greater (or similar) power and result in more ENS than the FR. Overall, WE designs can perform comparably to the optimal MAB design in terms of the ENS, but with greater statistical power for both large and small sample sizes. They have similar statistical power to the FR, but with the considerably greater ENS. The ENS and power trade-off can be tuned via the built-in parameter κ. Although, some modification to the MAB designs were proposed (e.g. see Villar and others, 2015) to prevent the low statistical power, the majority of those are ruled-based. The proposed approach allows to avoid any algorithm-based rules and keeps the procedure fully adaptive. Additionally, the computation of the Gittens index for the MAB design is not trivial, requires special attention and is widely discussed in the literature (e.g. see Villar and others, 2015, and reference there in). Some of them require calibration and can be computationally intensive. In contrast, the proposed criterion is extremely simple and easy to compute. While the proposed designs are compared for the target γ = 0.999, similar performance is obtained for the problem of seeking an arm associated with a given response probability (γ ∈ (0.7, 1)). This is, for example, of interest when seeking the effective dose 80 (ED80), the dose for which 80% of subjects respond to the treatment.
Phase I clinical trial 4.2.1 Setting
To study the WE design in the context of Phase I clinical trials, let us consider m = 7 arms, N = 20 patients and the arm selection allowed after each patient. The goal is to find the arm (which could be combination, schedule or combination-schedule) with a toxicity probability closest to γ = 0.25. In these studies randomization to all arms is not ethical for safety reasons and therefore, Rule II and κ = 0.5 are used. We would like to emphasize that we do not consider the classic dose-escalation problem in which the doses can be put according to increasing toxicity and focus on the setting in which clinicians cannot put arms according to increasing toxicity (as e.g. often in scheduling trials). While clinicians will be able to provide a presumed ordering of the arms, this order might be misspecified.
We consider scenarios in which the prior order chosen by clinicians is either correct or misspecified. The scenarios with correctly specified ordering have a monotonic armtoxicity relationship and the scenarios with misspecified ordering have a non-monotonic relationship. The investigated scenarios are shown in Figure 2 and include a variety of monotonic and non-monotonic shapes as well as one setting with highly toxic arms only. It is assumed that limited information about treatments is available and a linear increase in the toxicity probabilities is expected such thatp β 1 <p β 2 < . . . <p β 7 . For safety reasons, the trial is required to start at d 1 . An 'operational' prior, that is a prior that gives good operating characteristics under different scenarios, is calibrated. Details on the calibration are given in the Appendix. The resulting prior uses β = 1 and prior toxicity risk modes ofp = [0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55] T . For the simulation study below, the penalty parameter is fixed at κ = 0.5 due to the small sample size.
The WE design is compared to common Phase I designs. Specifically the Bayesian Continual Reassessment Method (CRM) (O'Quigley and others, 1990) and Escalation with Overdose Control (EWOC) (Babb and others, 1998) are considered as methods that assume a monotonic toxicity relationship. Additionally, the partial ordering CRM (POCRM, Wages and others, 2011) which relaxes the monotonicity assumption is also considered. It uses the original CRM design with additional randomization among a pre-specified set of orderings. In our comparison we consider only correct orderings (Table 3 ) to allow for the best possible performance of the POCRM under the evaluated scenarios. The same prior toxicity probabilitiesp and a rough prior distribution of the (1,2,7,6,5,4,3) 3 (7,6,5,4,1,2,3) model parameters were chosen for the model-based alternatives. Finally, we include the non-parametric optimal benchmark (O'Quigley and others, 2002) which provides the best theoretical performance if the patients' complete toxicity profiles are known.
The main characteristics to consider are: (i) the proportional of correct selections and (ii) the average number of toxic responses. The bcrm package (Sweeting and others, 2013) is used for CRM and EWOC and the pocrm package is used for POCRM. For the proposed method and the non-parametric optimal design one-million-fold simulations are used while 100,000-fold simulations are used for the model-based methods due to computational constraints.
Safety constraint
For ethical reasons an escalation procedure should be planned so that only few patients are assigned to highly toxic treatments which is typically achieved by the use of a safety constraint. The majority of existing safety constraints are based on the assumption of monotonicity and hence are not suitable for the proposed design. We adopt the following safety constraint instead. The treatment A j is safe if after n patients 1 γ * f n j (p)dp ≤ θ n j where γ * is an upper toxicity threshold, θ n j controls the overdosing probability and f n j is the posterior Beta distribution for the toxicity probability. Note that the overdosing threshold θ n j changes as the trial progresses. It should be a decreasing function of n with θ 0 = 1 to give a possibility to test all the treatments (if data suggests so) and θ f inal ≤ 0.3 to ensure that the final recommendation is safe. As an illustration, the linear non-increasing θ n = max(1 − rn, θ f inal ) is used with r > 0. We have calibrated the parameters of the safety constraints (details in the Appendix) and used γ * = 0.45 and r = 0.035 in the simulations. Similar safety constraints were incorporated in the model-based methods.
Results
The simulation results in monotonic scenarios 1-3 are given in Table 4 . The WE design performs comparably to the CRM and POCRM designs and recommends the correct treatment with the probability nearly 0.25 and 0.30 in scenario 1 and 2. In scenario 1 the WE design underestimates the target treatment and recommends a less toxic treatment more often due to the safety constraint. Despite that, the performance of all methods is not far from the non-parametric optimal benchmark which shows that the detection of the target treatment is quite challenging. Proportions of terminations are close to 0 and the average number of toxic responses is largely the same. For the EWOC, the level of the target treatment is underestimated in both scenarios. Table 4 : The operating characteristics of the WE, CRM, POCRM and EWOC designs. 'Term', 'T' andN correspond to the termination proportion, the average number of toxic responses and the average number of patients, respectively. The most likely recommendation is in bold, the actual target regimen is in italics. In scenario 3, the WE design shows a better performance than the model-based alternatives with nearly 45% of correct recommendations against about 40% for CRM and POCRM. The safety constraint allows to prevent the recommendation of highly toxic treatments and controls the total number of toxic responses. Again, the EWOC underestimates the target therapy, but results only in 3 toxic responses compared to 5 for the CRM and 6 toxicities for the WE and the POCRM. As expected, methods that relax monotonic assumption result in more toxic responses that monotonicity based designs.
The results for non-monotonic (Scenarios 4-5) and unsafe (Scenario 6) cases are given in Table 5 . As expected, the designs based on the monotonicity assumption are not able to find the target treatment in non-monotonic settings. Comparing other designs, the WE design has a substantial advantage. It finds the correct arm with the probability nearly 0.28 compared to 0.20 for the POCRM while exposing nearly the same number of patients to toxic treatments. The safety constraint allows recommendation of the optimal treatment even in non-monotonic scenarios where the target treatment lies beyond the toxic treatments (d 3 − d 4 ).
Considering Scenario 6, the WE design terminates earlier with probability 0.8 and performs similar to the POCRM and EWOC. It outperforms the CRM which recommends Table 5 : The operating characteristics of the WE, CRM, POCRM and EWOC designs. 'Term', 'T' andN correspond to the termination proportion, the average number of toxic responses and the average number of patients, respectively. The most likely recommendation is in bold, the actual target regimen is in intalics. a highly toxic arm with a larger probability (32.56% against 19.16%). However, methods that relax the monotonicity assumption result in more toxic responses and require more patients on average to come to the termination conclusion. While the CRM and the EWOC require 5 and 6 patients only, it takes nearly 14 and 13 patients for the WE and POCRM as they explore all arms before concluding none is safe. This, however, would not be considered as a severe drawbacks of these methods as in many application clinicians would stop the trial for safety reasons based on extensive patients profile. Summarizing, the proposed design performs comparably to the model-based approaches in monotonic settings and clearly outperforms them in non-monotonic ones. Importantly, despite the denominator of the proposed criterion which might favour slightly more toxic arms, the design does not cause any practical concerns as soon as the allocation is restricted to the safety set. In other words, the criterion allocates the patients to the best estimated TA taking into account information about the uncertainty in the estimates and about the safety set. Importantly, the time-varying safety constraint achieves the goals motivated by the ethical concerns while not preventing the target treatment selection in safe and non-monotonic scenarios. One can conclude that the design is ethical and can be applied in practice.
Discussion
In this work, we propose a family of criteria for selecting the best arm in experiments with multinomial outcomes. The novel criterion leads to accurate selection without the need for parametric or monotonicity assumptions. The fundamental property of the criterion is the infinite penalization of the bounds which was argued to be a crucial property for a parameter defined on the restricted space (Aitchison, 1992) . This property drives the allocation away from the bounds of a restricted space to the neighbourhood of the target value. The consistency conditions of the proposed design and exact rate for the special case of binary outcomes are obtained. It is shown how one can benefit from the proposed design in Phase I and Phase II clinical trials. The proposal was demonstrated to have a comparable or better characteristics than other alternatives. It preserves flexibility and allows to tailor the design parameters in light of the investigation goal. Additionally, the design is computationally simple and a large set of simulation can be performed in a feasible time.
Despite clinical trials being used as the main motivation throughout, the design can be applied to a wide range of problems of a similar nature. For example, applications where the MAB approach has found application: online advertising, portfolio design, queuing and communication networks, etc. (see Gittins and others, 2011 , and references there in). On top of that, the proposed design can be used in more general problems of percentile estimation rather than the identification of the highest success probability. It is important to emphasize that the derived selection criterion can be also applied in conjunction with a parametric models which also expands its possible applications. In fact, the parameters can be estimated by any desirable method and then 'pluged-in' in the criterion which preserves its properties.
We start from from κ = 1/2 and adopt notationδ
Using DeMorgan's law and Boole's inequality (Resnick, 2013) , one can obtain
with Φ(.) denoting the distribution function of a standard normal random variable,
1/2 and Σ k the variance corresponding to arm k as in the Theorem 2.3. As arms k and i are independent, there are two independent random variables in the left-hand side of the second term in (A.2) and each of them converges to a Gaussian random variables (Theorem 2.3). Therefore, the sum converges to a standard Gaussian random variable after an appropriate normalization. Consequently, for j = 1, . . . , m
By the construction of π j , δ j,j − δ i,j < 0. The number of observations on each arm N i is proportional to the total sample size N under Rule I: N j w j N and N j w j−1 N where a n b n means that lim n→∞ an bn = 1. Thus,
where c is a negative constant. Plugging-in terms in the accuracy formula, we obtain that lim N →∞ A N ≥ 1. For κ > 1/2, the probability of the final selection in the experiment is still given by (A.1) for κ = 1/2 as the penalty term is not taken into account for the final recommendation. Then, the only difference is the number of observation on each arm, proportional to the total number of patients N j l j (N )N with l j depending on N . This results in a different constant c < 0 in (A.4), but in the unchanged rate √ N due to the same rate in both nominator and denominator in Equation (2.8) with respect to N .
Binary outcomes
While the asymptotic result (A.2) is given in terms of Σ k,i , it can be written explicitly.
In the special case of binary outcomes d = 2, Σ k,i = σ
Therefore,
From the expression above, the rate obtained in (A.4) is explicit.
. The design based on this measure and on its point estimate is inconsistent as it does not guarantee an infinite number of patients on all arms. We use an example with two arms only with the arm A 1 being the optimal. Suppose that prior parameters are specified such thatδ β 2 δ β 1 and δ 2 δ β 1 , so A 2 is selected initially.
While the number of observations on the arm 2 increases and the estimateδ 2 approaches the true value δ 2 (Theorem 2.3), the estimateδ 1 remains unchanged. One can find prior valuesδ β 1 δ 2 such that A 1 is never selected, because the point estimateδ 2 would not go belowδ β 1 . Consequently, the selection would get stuck at the suboptimal arm regardless of further outcomes. So, the number of patients on both arms does not tend to infinity as N → ∞. 
is a random variable corresponding to the posterior density function after t observations in the experiment. Let n j (t) = t i=1 N j (i) be the number of observations on arm j up to the moment t. We then obtain
i (u)) has already been studied in (a). The mean ofδ (κ) j (u) associated with an arm A j to be selected is an increasing polynomial with respect to N . The probability to be the minimum decreases for j and increases for i = 1, . . . , j − 1, j + 1, . . . , m. It follows that the probability of being selected is not a monotonic function and
The final selection is the arm satisfying (2.9). Consequently, the number of observations on each arm tends to infinity and we obtain that lim N →∞ A N = 1 using the arguments of (a).
B Parameters calibration for the Phase I clinical trial B.1 Operational prior
A prior for treatment d j can be specified through the mode of the prior distribution,
. To guarantee the procedure to start from d 1 we setp β 1 = γ. As an investigator has the same amount of knowledge about each treatment we set β 1 = . . . = β 7 = β. Larger values of β and the rate of increase correspond to the more conservative escalation scheme as an investigator needs more observations on each particular treatment to escalate. Similarly, a greater differences in prior toxicity probabilities would correspond to the more conservative scheme as well, because it would require more evidence to escalate. Therefore, one can expect a set prior parameters that would lead to a similar PCS. The investigation of these parameter influence on the operational characteristics of the proposed approach is given below.
We consider six different scenarios with different location of the target (Figure 3 ). For simplicity, we would assume a priori that toxicity increases linearly between treatments. Given m = 7, we set the difference between prior toxicities on the d 1 and d 7 and, then, interpolate the linear curve for the rest. We would define step =p β 7 −p β 1 . Then, we vary values of step and β for each scenarios. The PCS for different combination of step and β is given in the Brighter colours correspond to higher values of the PCS. A conservative prior (top right corner on the grid) prevents the WE design from the correct recommendation in upper line graphs scenarios as higher doses can be hardly reached with N = 20. At the same time, it leads to an accurate selection in scenarios with highly toxic doses (lower line scenarios). In contrast, less conservative prior results in higher proportion of correct recommendation in upper line scenarios and worse in lower line ones. Therefore, there is a trade-off between the ability to investigate higher doses and the desire to prevent the high number of toxic responses. Therefore, the geometric mean of the PCS over all scenarios is chosen as the criterion for the operational prior choice. The geometric mean for different set of parameters is given in the Figure 4 .
There is a set of the prior parameter that lead to the same geometric mean of the We also consider the case of N = 25 thought the same set of scenarios to illustrate the influence of the prior parameter for a larger sample size ( Figure 5 ). There is a a similar dependence pattern on β and step. However, the set of the equivalent operational prior parameters is now wider that means the importance of the prior distribution decreases with the sample size as one would expect.
B.2 Safety constraint
Parameters r and γ * determine the strictness of the safety constraint. Greater values of r and smaller values of γ * would lead to more conservative escalation. It helps to avoid high risk in unsafe scenarios, but also to prevent the correct recommendation in flat safe scenarios. There is a clear trade-off in the choice of these parameters that is precisely studied below.
Let us consider two extreme scenarios: a linear flat dose response shape with the target treatment far from the bottom (d 5 ) and the scenario with no safe treatment at all. The operating characteristics of the proposed method in these two scenarios with different parameters of the safety constraint γ * and r are given in Table 6 . Figure 5 : The geometric mean of the proportion of correct recommendations by the proposed WE method using different set of prior parameters: β (vertical axis) and the difference between the risk of toxicity on the lowest and highest dose (horizontal axis) in six scenarios. Total sample size N = 25. 10 6 simulations are used. The upper line in each cell corresponds to the proportion of times the proposed method declares that there is no safe dose when there is actually no safe dose. The lower line corresponds to the proportion of trials the actual TD25 was recommended in a linear scenario. The most relaxed safety constraint corresponds to the left upper corner. In this case no trials are terminated in a highly toxic scenario and the proportion of times the TD25 is recommended in the linear scenario is high. The right lower corner corresponds to the strictest safety constraint. In this case near all trials will be terminated when there is no safe dose, but the method will often not find the TD25 in the linear scenario. Therefore, the trade-off is to sacrifice the accuracy of the method when the TD25 is far from the bottom in order to prevent the recommendation of highly toxic dose in unsafe scenario.
